サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1402531

北米の肺がん検診市場の2030年までの予測-地域別分析-がんタイプ、技術、年齢層、エンドユーザー別

North America Lung Cancer Screening Market Forecast to 2030 - Regional Analysis - by Cancer Type, Technology, Age Group (50 & Older and Below 50), and End User (Hospitals, Diagnostic Centers, and Others)
出版日: | 発行: The Insight Partners | ページ情報: 英文 100 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
北米の肺がん検診市場の2030年までの予測-地域別分析-がんタイプ、技術、年齢層、エンドユーザー別
出版日: 2023年11月07日
発行: The Insight Partners
ページ情報: 英文 100 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

北米の肺がん検診市場は、2022年の9億6,541万米ドルから2030年には18億1,148万米ドルに成長すると予測されています。2022年から2030年までのCAGRは8.2%と推定されます。

政府支援の増加が北米の肺がん検診市場を後押し

肺がんは、世界全体の主要な死亡原因のひとつです。肺がん検診は、がん予防アプローチの重要な要素です。肺がん患者の予後は、早期に診断された場合に良好であるため、肺がんのリスクが高い人は、肺にがんができるのを発見するために定期的な検査を受けることが奨励されています。米国がん協会による2023年の米国における肺がんの推定によると、約238,340人の肺がん患者が新たに登録され、そのうち女性では120,790人、男性では117,550人が報告されています。このように、世界の肺がん罹患率の上昇が肺がん検診プログラムの開始に寄与しており、これが市場成長の原動力となっています。

北米の肺がん検診市場概要

北米の肺がん検診市場は米国、カナダ、メキシコに区分されます。この地域の成長は、肺がんの罹患率の増加や喫煙の副作用に対する人々の認識など、さまざまな要因によるものです。また、検診に対する政府支援の高まりが市場のさらなる成長につながっています。

北米では、米国が北米の肺がん検診市場で大きなシェアを占めています。この国の市場成長は、主に肺がんの罹患率の増加と政府のイニシアチブによってもたらされています。肺がんは、米国では男女ともに2番目に多いがんです。米国がん協会（American Cancer Society, Inc.）によると、2023年現在、米国の成人約238,340人（男性117,550人、女性120,790人）が肺がんと診断され、～127,070人（男性67,160人、女性59,910人）が肺がんが原因で死亡しています。肺がんは全がん死亡の5人に1人を占め、米国におけるがん死亡の主要原因となっています。この統計には小細胞肺がんとNSCLCの両方が含まれます。NSCLCは最も一般的な肺がんのタイプで、肺がん診断全体の81％を占める。米国の全肺がんの5年相対生存率は23％で、NSCLCの5年相対生存率は男性23％、女性33％です。米国では、低線量ヘリカルまたはスパイラルCT（CTまたはCAT）スキャンと呼ばれる検査による肺がん検診が推奨されています。予防サービス専門委員会（USPSTF）は、50～80歳で喫煙歴が20箱年以上ある人、または過去15年以内に禁煙した人は、毎年低線量CTスキャンによる肺がん検診を受けることを推奨しています。2023年5月、デジタル戦略室が管理するホワイトハウスの公式ウェブサイトwhitehouse.govに掲載された報告書によると、地域がんセンター協会（ACCC）とアストラゼネカは、「アパラチア地方肺がん検診イニシアチブ」を通じて、アメリカの地方における肺がん検診を増加させるために、人を中心とした持続可能なアプローチを開発し、実施するためのパートナーシップを締結します。アパラチア地域（ウェストバージニア州全域と他の12州の一部を含む）のがん死亡率は、米国の他の地域よりも10％高いです。このイニシアチブの目的は、肺がんの5年生存率を2倍にすることです。このような取り組みが米国の北米の肺がん検診市場の成長に寄与しています。

北米の肺がん検診市場の収益と2030年までの予測（金額）

北米の肺がん検診市場のセグメンテーション

北米の肺がん検診市場は、がんタイプ、技術、年齢層、エンドユーザー、国別に区分されます。

がんの種類に基づき、北米の肺がん検診市場は非小細胞肺がん（NSCLC）、小細胞肺がんに区分されます。2022年の北米の肺がん検診市場では、非小細胞肺がん（NSCLC）セグメントが大きなシェアを占めています。

技術に基づき、北米の肺がん検診市場は胸部X線、低線量コンピュータ断層撮影（LDCT）、リキッドバイオプシー、その他に区分されます。2022年の北米の肺がん検診市場では、低線量コンピュータ断層撮影（LDCT）分野が最大シェアを占めました。

年齢層に基づき、北米の肺がん検診市場は50歳以上と50歳以下に区分されます。50歳以上セグメントは2022年に北米の肺がん検診市場でより大きなシェアを占めました。

エンドユーザーに基づき、北米の肺がん検診市場は病院、診断センター、その他に区分されます。病院セグメントは2022年に北米の肺がん検診市場で最大のシェアを占めました。

国別では、北米の肺がん検診市場は米国、カナダ、メキシコに区分されます。米国が2022年の北米の肺がん検診市場を独占しました。

Siemens AG、Koninklijke Philips NV、Canon Inc、Medtronic、GE HealthCare、Nuance Communications Inc、LungLife AI, Inc、Intelerad Medical Systems、bioAffinity Technologies, Inc、CSV Healthは、北米の肺がん検診市場で事業を展開する主要企業の一部です。

目次

目次

第1章 イントロダクション

第2章 北米の肺がん検診市場-要点

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 北米の肺がん検診市場-市場情勢

  • イントロダクション
  • 北米のPEST分析
  • 専門家の見解

第5章 北米の肺がん検診市場-主要市場力学

  • 市場促進要因
    • 肺がん罹患率の上昇
    • 政府支援の増加
  • 市場抑制要因
    • 肺がん検診検査の高コスト
  • 市場機会
    • 肺がん検診プログラムの構造化
  • 今後の動向
    • 最先端技術の利用
  • 影響分析

第6章 肺がん検診市場-北米分析

  • 北米の肺がん検診市場の収益予測と分析

第7章 北米の肺がん検診市場：2028年までの収益と予測：がんタイプ別

  • イントロダクション
  • 北米の肺がん検診市場：2022年と2030年のがんタイプ別売上高シェア（%）
  • 非小細胞肺がん（NSCLC）
  • 小細胞肺がん

第8章 北米の肺がん検診市場分析：技術別

  • イントロダクション
  • 低線量コンピュータ断層撮影（LDCT）
  • 胸部X線検査
  • リキッドバイオプシー
  • その他

第9章 北米の肺がん検診市場分析：年齢層別

  • イントロダクション
  • 高齢者
  • 50歳以下

第10章 北米の肺がん検診市場分析：エンドユーザー別

  • イントロダクション
  • 病院
  • 診断センター
  • その他

第11章 北米の肺がん検診市場：2028年までの収益と予測：国別分析

  • 北米の肺がん検診市場概要

第12章 北米の肺がん検診市場-業界情勢

  • 最近の成長戦略

第13章 企業プロファイル

  • Intelerad Medical Systems
  • Nuance Communications Inc
  • GE HealthCare
  • Medtronic
  • Canon Inc.
  • Koninklijke Philips NV
  • Siemens AG
  • CVS Health
  • bioAffinity Technologies, Inc.
  • LungLife AI, Inc.

第14章 付録

図表

List Of Tables

List of Tables

  • Table 1. US North America Lung Cancer Screening Market, by Cancer Type - Revenue and Forecast to 20228 (US$ Million)
  • Table 2. US North America Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
  • Table 3. US North America Lung Cancer Screening Market, by Age Group - Revenue and Forecast to 2030 (US$ Million)
  • Table 4. US North America Lung Cancer Screening Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 5. Canada North America Lung Cancer Screening Market, by Cancer Type - Revenue and Forecast to 20228 (US$ Million)
  • Table 6. Canada North America Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
  • Table 7. Canada North America Lung Cancer Screening Market, by Age Group - Revenue and Forecast to 2030 (US$ Million)
  • Table 8. Canada North America Lung Cancer Screening Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 9. Mexico North America Lung Cancer Screening Market, by Cancer Type - Revenue and Forecast to 20228 (US$ Million)
  • Table 10. Mexico North America Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
  • Table 11. Mexico North America Lung Cancer Screening Market, by Age Group - Revenue and Forecast to 2030 (US$ Million)
  • Table 12. Mexico North America Lung Cancer Screening Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 13. Recent Growth Strategies in the North America Lung Cancer Screening Market
  • Table 14. Glossary of Terms

List Of Figures

List of Figures

  • Figure 1. North America Lung Cancer Screening Market Segmentation
  • Figure 2. North America Lung Cancer Screening Market, by Country
  • Figure 3. North America Lung Cancer Screening Market Overview
  • Figure 4. Non-Small Cell Lung Cancer Segment Held Largest Share of Cancer Type Segment in North America Lung Cancer Screening Market
  • Figure 5. North America Expected to Show Remarkable Growth During Forecast Period
  • Figure 6. North America: PEST Analysis
  • Figure 7. Experts' Opinion
  • Figure 8. North America Lung Cancer Screening Market Impact Analysis of Driver and Restraints
  • Figure 9. North America Lung Cancer Screening Market - Revenue Forecast and Analysis - 2020-2030
  • Figure 10. North America Lung Cancer Screening Market Revenue Share, by Cancer Type 2022 & 2030 (%)
  • Figure 11. Non-Small Cell Lung Cancer (NSCLC): North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Small Cell Lung Cancer: North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. North America Lung Cancer Screening Market, by Technology, 2022 & 2030 (%)
  • Figure 14. Low-Dose Computed Tomography (LDCT): North America Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Chest X-ray: North America Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Liquid Biopsy: North America Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Others: North America Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. North America Lung Cancer Screening Market, by Age group, 2022 & 2030 (%)
  • Figure 19. & Older: North America Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Below 50: North America Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. North America Lung Cancer Screening Market, by End User, 2022 & 2030 (%)
  • Figure 22. Hospitals: North America Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Diagnostic Centers: North America Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Others: North America Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. North America Lung Cancer Screening Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 26. North America Lung Cancer Screening Market Revenue Share, by Key Country, (2022 & 2030)
  • Figure 27. US: North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 28. Canada: North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 29. Mexico: North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
目次
Product Code: BMIRE00029064

The North America lung cancer screening market is expected to grow from US$ 965.41 million in 2022 to US$ 1,811.48 million by 2030. It is estimated to grow at a CAGR of 8.2% from 2022 to 2030.

Increasing Government Support Fuel North America lung cancer screening market.

Lung cancer is among the main causes of mortality across the world. Lung cancer screening is a critical component of cancer prevention approaches. The prognosis for lung cancer patients is better when the disease is diagnosed early, so people at high risk of lung cancer are encouraged to undergo routine testing to detect the formation of cancerous growth in their lungs. According to estimates by the American Cancer Society for lung cancer in the US for 2023, about 238,340 new lung cancer cases were registered; of these, 120,790 in women and 117,550 in men were reported. Thus, the rising incidence of lung cancer worldwide is contributing to the initiation of lung cancer screening programs, which is, in turn, driving the market growth.

North America Lung Cancer Screening Market Overview

The North America, Lung Cancer Screening Market is segmented into the US, Canada, and Mexico. The regional growth is attributed to various factors, such as the increasing incidence of lung cancer and awareness of side effects of cigarette smoking among people. Also, rising government support for screening has led to the further growth of the market.

In North America, the US holds a significant share of the North America Lung Cancer Screening Market . The market growth in this country is primarily driven by the increasing incidence of lung cancer and government initiatives. Lung cancer is the second most common cancer in both men and women in the US. As per the American Cancer Society, Inc., as of 2023, approximately 238,340 adults (117,550 men and 120,790 women) in the US have been diagnosed with lung cancer, and ~127,070 (67,160 in men and 59,910 in women) have succumbed to death due to the disease. Lung Cancer accounts for 1 in 5 of all cancer death, making it a leading cause of cancer death in the US. These statistics include both small cell lung cancer and NSCLC. NSCLC is the most common type of lung cancer, accounting for 81% of all lung cancer diagnoses. For all types of lung cancer in the US, the 5-year relative survival rate is 23%, and for NSCLC, the 5-year relative survival rate for men and women is 23% and 33%, respectively. In the US, screening for lung cancer is recommended with a test called a low-dose helical or spiral computed tomography (CT or CAT) scan. Preventive Services Task Force (USPSTF) recommends that people aged 50-80, with a history of smoking 20 pack years or more, or who have quit within the past 15 years should go through screening for lung cancer with low-dose CT scans each year. As per the report published in the whitehouse.gov, the official website of the White House, managed by the Office of Digital Strategy in May 2023, the Association of Community Cancer Centers (ACCC) and AstraZeneca are entering into a partnership to develop and implement person-centered and sustainable approaches to increase lung cancer screening in rural America through the "Rural Appalachian Lung Cancer Screening Initiative." The cancer mortality rate in the Appalachian region, including all of West Virginia and parts of 12 other states, is 10% higher than that in the rest of the US. The aim of this initiative is to double the five-year survival rate for lung cancer. Such initiatives are contributing to the North America Lung Cancer Screening Market growth in the US.

North America Lung Cancer Screening Market Revenue and Forecast to 2030 (US$ Million)

North America Lung Cancer Screening Market Segmentation

The North America lung cancer screening market is segmented into cancer type, technology, age group, end user, and country.

Based on cancer type, the North America lung cancer screening market is segmented into non-small cell lung cancer (NSCLC), and small cell lung cancer. The non-small cell lung cancer (NSCLC) segment held a larger share of the North America lung cancer screening market in 2022.

Based on technology, the North America lung cancer screening market is segmented into chest X-ray, low dose computed tomography (LDCT), liquid biopsy, and others. Low dose computed tomography (LDCT) segment held the largest share of the North America lung cancer screening market in 2022.

Based on age group, the North America lung cancer screening market is segmented into 50 and older, and below 50. 50 and older segment held the larger share of the North America lung cancer screening market in 2022.

Based on end user, the North America lung cancer screening market is segmented into hospital, diagnostic centre, and others. Hospital segment held the largest share of the North America lung cancer screening market in 2022.

Based on country, the North America Lung Cancer Screening Market is segmented into the US, Canada, and Mexico. The US dominated the North America lung cancer screening market in 2022.

Siemens AG, Koninklijke Philips NV, Canon Inc, Medtronic, GE HealthCare, Nuance Communications Inc, LungLife AI, Inc, Intelerad Medical Systems, bioAffinity Technologies, Inc, and CSV Health are some of the leading companies operating in the North America lung cancer screening market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America Lung Cancer Screening Market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in North America Lung Cancer Screening Market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth North America Market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Table Of Contents

Table of Contents

1. Introduction

  • 1.1 Study Scope
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 North America Lung Cancer Screening Market - by Technology
    • 1.3.2 North America Lung Cancer Screening Market - by Cancer Type
    • 1.3.3 North America Lung Cancer Screening Market - by Age Group
    • 1.3.4 North America Lung Cancer Screening Market - by End User
    • 1.3.5 North America Lung Cancer Screening Market - by Country

2. North America Lung Cancer Screening Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Lung Cancer Screening Market - Market Landscape

  • 4.1 Overview
  • 4.2 North America PEST Analysis
  • 4.3 Expert's Opinion

5. North America Lung Cancer Screening Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Lung Cancer Incidences
    • 5.1.2 Increasing Government Support
  • 5.2 Market Restraints
    • 5.2.1 High Cost of Lung Cancer Screening Tests
  • 5.3 Market Opportunities
    • 5.3.1 Structured Lung Cancer Screening Program
  • 5.4 Future Trends
    • 5.4.1 Use of Cutting-Edge Technologies
  • 5.5 Impact Analysis

6. Lung Cancer Screening Market - North America Analysis

  • 6.1 North America Lung Cancer Screening Market Revenue Forecast and Analysis

7. North America Lung Cancer Screening Market - Revenue and Forecast to 2028 - By Cancer Type

  • 7.1 Overview
  • 7.2 North America Lung Cancer Screening Market Revenue Share, by Cancer Type 2022 & 2030 (%)
  • 7.3 Non-Small Cell Lung Cancer (NSCLC)
    • 7.3.1 Overview
    • 7.3.2 Non-Small Cell Lung Cancer (NSCLC): North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Mn)
  • 7.4 Small Cell Lung Cancer
    • 7.4.1 Overview
    • 7.4.2 Small Cell Lung Cancer: North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Lung Cancer Screening Market Analysis - by Technology

  • 8.1 Overview
  • 8.2 Low-Dose Computed Tomography (LDCT)
    • 8.2.1 Overview
    • 8.2.2 Low-Dose Computed Tomography (LDCT): North America Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
  • 8.3 Chest X-ray
    • 8.3.1 Overview
    • 8.3.2 Chest X-ray: North America Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Liquid Biopsy
    • 8.4.1 Overview
    • 8.4.2 Liquid Biopsy: North America Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Others
    • 8.5.1 Overview
    • 8.5.2 Others: North America Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)

9. North America Lung Cancer Screening Market Analysis - by Age Group

  • 9.1 Overview
  • 9.2 & Older
    • 9.2.1 Overview
    • 9.2.2 & Older: North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.3 Below 50
    • 9.3.1 Overview
    • 9.3.2 Below 50: North America Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Lung Cancer Screening Market Analysis - by End User

  • 10.1 Overview
  • 10.2 Hospitals
    • 10.2.1 Overview
    • 10.2.2 Hospitals: North America Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.3 Diagnostic Centers
    • 10.3.1 Overview
    • 10.3.2 Diagnostic Centers: North America Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.4 Others
    • 10.4.1 Overview
    • 10.4.2 Others: North America Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)

11. North America Lung Cancer Screening Market - Revenue and Forecast to 2028 - Country Analysis

  • 11.1 North America Lung Cancer Screening Market Overview
      • 11.1.1.1 US: North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.1.1 Overview
        • 11.1.1.1.2 US: North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.1.3 US: North America Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
        • 11.1.1.1.4 US: North America Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.1.5 US: North America Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
        • 11.1.1.1.6 US: North America Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
      • 11.1.1.2 Canada: North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.2.1 Overview
        • 11.1.1.2.2 Canada: North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.2.3 Canada: North America Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
        • 11.1.1.2.4 Canada: North America Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.2.5 Canada: North America Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
        • 11.1.1.2.6 Canada: North America Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
      • 11.1.1.3 Mexico: North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.3.1 Overview
        • 11.1.1.3.2 Mexico: North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.3.3 Mexico: North America Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
        • 11.1.1.3.4 Mexico: North America Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.3.5 Mexico: North America Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
        • 11.1.1.3.6 Mexico: North America Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)

12. North America Lung Cancer Screening Market-Industry Landscape

  • 12.1 Recent Growth Strategies
    • 12.1.1 Overview

13. Company Profiles

  • 13.1 Intelerad Medical Systems
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Nuance Communications Inc
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 GE HealthCare
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Medtronic
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Canon Inc.
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Koninklijke Philips NV
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Siemens AG
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 CVS Health
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 bioAffinity Technologies, Inc.
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 LungLife AI, Inc.
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms